|
1
|
Boyle P and Howell A: The globalisation of
breast cancer. Breast Cancer Res. 12(Suppl 4): S72010. View Article : Google Scholar :
|
|
2
|
Youlden DR, Cramb SM, Yip CH and Baade PD:
Incidence and mortality of female breast cancer in the Asia-Pacific
region. Cancer Biol Med. 11:101–115. 2014.PubMed/NCBI
|
|
3
|
Brenton JD, Carey LA, Ahmed AA and Caldas
C: Molecular classification and molecular forecasting of breast
cancer: Ready for clinical application? J Clin Oncol. 23:7350–7360.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Criscitiello C, Azim HA Jr, Schouten PC,
Linn SC and Sotiriou C: Understanding the biology of
triple-negative breast cancer. Ann Oncol. 23(Suppl 6): vi13–vi18.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
De Laurentiis M, Cianniello D, Caputo R,
Stanzione B, Arpino G, Cinieri S, Lorusso V and De Placido S:
Treatment of triple negative breast cancer (TNBC): Current options
and future perspectives. Cancer Treat Rev. 36(Suppl 3): S80–S86.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Corkery B, Crown J, Clynes M and O'Donovan
N: Epidermal growth factor receptor as a potential therapeutic
target in triple-negative breast cancer. Ann Oncol. 20:862–867.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bernsdorf M, Ingvar C, Jörgensen L, Tuxen
MK, Jakobsen EH, Saetersdal A, Kimper-Karl ML, Kroman N, Balslev E
and Ejlertsen B: Effect of adding gefitinib to neoadjuvant
chemotherapy in estrogen receptor negative early breast cancer in a
randomized phase II trial. Breast Cancer Res Treat. 126:463–470.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Carey LA, Rugo HS, Marcom PK, Mayer EL,
Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A,
et al: TBCRC 001: Randomized phase II study of cetuximab in
combination with carboplatin in stage IV triple-negative breast
cancer. J Clin Oncol. 30:2615–2623. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dickler MN, Cobleigh MA, Miller KD, Klein
PM and Winer EP: Efficacy and safety of erlotinib in patients with
locally advanced or metastatic breast cancer. Breast Cancer Res
Treat. 115:115–121. 2009. View Article : Google Scholar
|
|
10
|
Hong W and Guan KL: The YAP and TAZ
transcription co-activators: Key downstream effectors of the
mammalian Hippo pathway. Semin Cell Dev Biol. 23:785–793. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chan SW, Lim CJ, Guo K, Ng CP, Lee I,
Hunziker W, Zeng Q and Hong W: A role for TAZ in migration,
invasion, and tumorigenesis of breast cancer cells. Cancer Res.
68:2592–2598. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang N, Morrison CD, Liu P, Miecznikowski
J, Bshara W, Han S, Zhu Q, Omilian AR, Li X and Zhang J: TAZ
induces growth factor-independent proliferation through activation
of EGFR ligand amphiregulin. Cell Cycle. 11:2922–2930. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
14
|
Cordenonsi M, Zanconato F, Azzolin L,
Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR,
Poletti A, et al: The Hippo transducer TAZ confers cancer stem
cell-related traits on breast cancer cells. Cell. 147:759–772.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pan D: The hippo signaling pathway in
development and cancer. Dev Cell. 19:491–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Piccolo S, Cordenonsi M and Dupont S:
Molecular pathways: YAP and TAZ take center stage in organ growth
and tumorigenesis. Clin Cancer Res. 19:4925–4930. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang K, Degerny C, Xu M and Yang XJ: YAP,
TAZ, and Yorkie: A conserved family of signal-responsive
transcriptional coregulators in animal development and human
disease. Biochem Cell Biol. 87:77–91. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Harvey KF, Zhang X and Thomas DM: The
Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Edgar BA: From cell structure to
transcription: Hippo forges a new path. Cell. 124:267–273. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lai D, Ho KC, Hao Y and Yang X: Taxol
resistance in breast cancer cells is mediated by the hippo pathway
component TAZ and its downstream transcriptional targets Cyr61 and
CTGF. Cancer Res. 71:2728–2738. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang JM, Nagatomo I, Suzuki E, Mizuno T,
Kumagai T, Berezov A, Zhang H, Karlan B, Greene MI and Wang Q: YAP
modifies cancer cell sensitivity to EGFR and survivin inhibitors
and is negatively regulated by the non-receptor type protein
tyrosine phosphatase 14. Oncogene. 32:2220–2229. 2013. View Article : Google Scholar
|
|
22
|
Zhang X, George J, Deb S, Degoutin JL,
Takano EA, Fox SB, Bowtell DD and Harvey KF; AOCS Study group: The
Hippo pathway transcriptional co-activator, YAP, is an ovarian
cancer oncogene. Oncogene. 30:2810–2822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hall CA, Wang R, Miao J, Oliva E, Shen X,
Wheeler T, Hilsenbeck SG, Orsulic S and Goode S: Hippo pathway
effector Yap is an ovarian cancer oncogene. Cancer Res.
70:8517–8525. 2010. View Article : Google Scholar : PubMed/NCBI
|
